Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Amplia Therapeutics Ltd. ( (AU:ATX) ) is now available.
Amplia Therapeutics has announced the successful completion of recruitment for its ACCENT Phase 2a clinical trial ahead of schedule. The trial is aimed at testing the efficacy of narmafotinib, their FAK inhibitor, in combination with standard chemotherapy for advanced pancreatic cancer patients. The trial has shown promising results with a 38.5% objective response rate, surpassing historical benchmarks, and a median trial duration of 197 days, indicating a 68% improvement over past data. The company plans to release top-line data by mid-Q3 2025, which could significantly impact its industry positioning and stakeholder interests.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company that specializes in developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company focuses particularly on fibrotic cancers, such as pancreatic and ovarian cancers, and also targets other chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 15.00%
Average Trading Volume: 29,393
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $20.33M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.
